GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » E10

CLRB (Cellectar Biosciences) E10 : $-2,766.04 (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is Cellectar Biosciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cellectar Biosciences's adjusted earnings per share data for the three months ended in Mar. 2025 was $-4.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2,766.04 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average E10 Growth Rate was 54.10% per year. During the past 5 years, the average E10 Growth Rate was 55.80% per year. During the past 10 years, the average E10 Growth Rate was 44.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cellectar Biosciences was 57.80% per year. The lowest was 14.80% per year. And the median was 49.15% per year.

As of today (2025-07-01), Cellectar Biosciences's current stock price is $4.94. Cellectar Biosciences's E10 for the quarter that ended in Mar. 2025 was $-2,766.04. Cellectar Biosciences's Shiller PE Ratio of today is .


Cellectar Biosciences E10 Historical Data

The historical data trend for Cellectar Biosciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences E10 Chart

Cellectar Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81,872.40 -40,941.75 -26,290.26 -12,251.79 -3,949.91

Cellectar Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,382.26 -5,538.08 -5,729.45 -3,949.91 -2,766.04

Competitive Comparison of Cellectar Biosciences's E10

For the Biotechnology subindustry, Cellectar Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectar Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Shiller PE Ratio falls into.


;
;

Cellectar Biosciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cellectar Biosciences's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-4.2/134.9266*134.9266
=-4.200

Current CPI (Mar. 2025) = 134.9266.

Cellectar Biosciences Quarterly Data

per share eps CPI Adj_EPS
201506 -9,073.611 100.684 -12,159.556
201509 -7,373.960 100.392 -9,910.633
201512 3,324.871 99.792 4,495.468
201603 2,883.087 100.470 3,871.838
201606 -1,470.000 101.688 -1,950.495
201609 -1,290.000 101.861 -1,708.753
201612 -1,668.144 101.863 -2,209.612
201703 -720.000 102.862 -944.440
201706 -696.000 103.349 -908.657
201709 -774.000 104.136 -1,002.858
201712 -1,020.000 104.011 -1,323.177
201803 -621.000 105.290 -795.800
201806 -507.000 106.317 -643.433
201809 -495.000 106.507 -627.084
201812 -242.651 105.998 -308.875
201903 -228.000 107.251 -286.836
201906 -138.000 108.070 -172.295
201909 -126.000 108.329 -156.936
201912 -99.000 108.420 -123.203
202003 -126.000 108.902 -156.111
202006 -78.000 108.767 -96.760
202009 -45.000 109.815 -55.290
202012 -21.000 109.897 -25.783
202103 -39.000 111.754 -47.087
202106 -34.200 114.631 -40.255
202109 -29.100 115.734 -33.926
202112 -28.800 117.630 -33.035
202203 -30.000 121.301 -33.370
202206 -36.600 125.017 -39.501
202209 -38.400 125.227 -41.374
202212 -30.300 125.222 -32.648
202303 -19.200 127.348 -20.343
202306 -27.000 128.729 -28.300
202309 -46.500 129.860 -48.314
202312 -12.300 129.419 -12.823
202403 -27.300 131.776 -27.953
202406 -5.400 132.554 -5.497
202409 -12.000 133.029 -12.171
202412 -0.300 133.157 -0.304
202503 -4.200 134.927 -4.200

Add all the adjusted EPS together and divide 10 will get our e10.


Cellectar Biosciences  (NAS:CLRB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cellectar Biosciences E10 Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Executives
Jarrod Longcor officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Andrei Shustov officer: Senior Vice President, Medical 7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea officer: Chief Commercial Officer 7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean officer: Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll director
Asher Chanan-khan director C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE, COLT NECK NJ 07722
John Neis director 505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev officer: Chief Medical Officer 15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355